DexCom Stock Forecast, Price & News

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 2 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DexCom stock.
View analyst ratings for DexCom or view top-rated stocks.

Wall Street analysts have given DexCom a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but DexCom wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

DexCom is scheduled to release its next quarterly earnings announcement on Tuesday, July 27th 2021.
View our earnings forecast for DexCom.

DexCom, Inc. (NASDAQ:DXCM) posted its earnings results on Thursday, April, 29th. The medical device company reported $0.33 EPS for the quarter, topping the Zacks' consensus estimate of $0.31 by $0.02. The medical device company earned $505 million during the quarter, compared to the consensus estimate of $482.67 million. DexCom had a net margin of 25.36% and a trailing twelve-month return on equity of 17.86%.
View DexCom's earnings history.

DexCom's stock was trading at $252.42 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, DXCM shares have increased by 65.7% and is now trading at $418.29.
View which stocks have been most impacted by COVID-19.

DexCom updated its FY 2021 earnings guidance on Thursday, May, 13th. The company provided EPS guidance of - for the period. The company issued revenue guidance of $2.26 billion-$2.36 billion, compared to the consensus revenue estimate of $2.32 billion.

16 Wall Street analysts have issued 12-month target prices for DexCom's shares. Their forecasts range from $380.00 to $500.00. On average, they expect DexCom's stock price to reach $461.19 in the next year. This suggests a possible upside of 10.3% from the stock's current price.
View analysts' price targets for DexCom or view top-rated stocks among Wall Street analysts.

347 employees have rated DexCom CEO Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among DexCom's employees.

Some companies that are related to DexCom include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), IDEXX Laboratories (IDXX), Baxter International (BAX), ResMed (RMD), Insulet (PODD), Teleflex (TFX), STERIS (STE), Hologic (HOLX) and Abiomed (ABMD).
View all of DXCM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), salesforce.com (CRM), ServiceNow (NOW), The Walt Disney (DIS), The Trade Desk (TTD) and Shopify (SHOP).

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

DexCom's stock is owned by a number of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (5.51%), Sands Capital Management LLC (3.04%), Morgan Stanley (2.48%), Lone Pine Capital LLC (2.45%), Artisan Partners Limited Partnership (2.03%) and Janus Henderson Group PLC (1.93%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Bridgette P Heller, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal.
View institutional ownership trends for DexCom.

DXCM stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Morgan Stanley, Jennison Associates LLC, Point72 Asset Management L.P., Lord Abbett & CO. LLC, Renaissance Technologies LLC, Baillie Gifford & Co., and Franklin Resources Inc.. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Bridgette P Heller, Jacob Steven Leach, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Quentin S Blackford, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli, and Sumi Shrishrimal.
View insider buying and selling activity for DexCom or view top insider-selling stocks.

DXCM stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Sands Capital Management LLC, Artisan Partners Limited Partnership, TCW Group Inc., Nuveen Asset Management LLC, Redmile Group LLC, Holocene Advisors LP, and Sei Investments Co..
View insider buying and selling activity for DexCom or or view top insider-buying stocks.

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DXCM stock can currently be purchased for approximately $418.29.

DexCom has a market capitalization of $40.45 billion and generates $1.93 billion in revenue each year. The medical device company earns $493.60 million in net income (profit) each year or $3.10 on an earnings per share basis.

DexCom employs 6,400 workers across the globe.

The following companies are subsidiares of DexCom: DexCapital LLC, DexCom (Canada) Inc., DexCom (UK) Distribution Ltd., DexCom (UK) Intermediate Holdings Ltd., DexCom (UK) Ltd., DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom Deutschland GmbH, DexCom International Ltd., DexCom Kommanditbolag, DexCom Operating Ltd., DexCom Philippines Inc, DexCom Suisse GmbH, Nintamed Handels GmbH, SweetSpot Diabetes Care Inc, The Glucose Program LLC, and TypeZero Technologies Inc.

DexCom was founded in 1999.

The official website for DexCom is www.dexcom.com.

DexCom is headquartered at 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121.

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]